Summary
We investigated the effect of 17β-N,N-diethylcarbamoyl-4-methyl-4aza-5α-androstan-3-one (4MA), a 5α-reductase inhibitor, on growth inhibition of androgen-sensitive rat prostatic tumour (R3327-H) and correlated it with changes in weight of normal androgen target tissues and with levels of androgens. Groups of male Copenhagen rats were treated for 28 days with a daily injection of various, increasing doses of 4MA (0.01–4.0 mg/day) and the results were compared with control (vehicle-treated) and with castrated animals. 4MA decreased tumour growth rate in a dose-dependent manner, which was reflected in a decreased incorporation of BrdUrd in DNA of glandular epithelial cells in the tumour. Normal prostate wet weight was also decreased after high-dose 4MA treatment while serum testosterone levels were not affected by 4MA treatment. Contrary to expectations, however, tissue levels of dihydrotestosterone in tumour and ventral prostate were still considerable in 4MA-treated animals. The tumour-inhibiting action of 4MA, therefore, has to be interpreted as not being purely due to 5α-reductase inhibition. On the other hand, it was not possible to demonstrate any direct tumoricidal effect of 4MA in vitro. The relevance of these findings in terms of the endocrine mechanism of action of 4MA on tumour growth is discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- 4MA:
-
17β-N,N-diethylcarbamoyl-4-methyl-4-aza-5α-androstan-3-one
- DHT:
-
dihydrotestosterone
- PBS:
-
phosphate-buffered saline
- TBS:
-
TRIS-buffered saline
References
Andriole GL, Rittmaster RS, Loriaux DL, Kish ML, Linehan WM (1987) The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice. Prostate 10:189–197
Barrett-Connor E, Garland C, McPhilipps JB, Khaw K-T, Wingard DL (1990) A prospective, population-based study of androstenedione, estrogens and prostatic cancer. Cancer Res 50:169–173
Brooks JR, Baptista EM, Berman C, Ham EA, Hichens M, Johnston DBR, Primka RL, Rasmusson GH, Reynolds GF, Schmitt SM, Arth GE (1981) Response of rat ventral prostate to a new and novel 5α-reductase inhibitor. Endocrinology 109:830–836
Brooks JR, Berman C, Hichens M, Primka RL, Reynolds GF, Rasmusson GH (1982) Biological activities of a new steroidal inhibitor ofΔ 4-5α-reductase(41309). Proc Soc Exp Biol Med 169:67–73
Chevalier S, Turcotte G, McKercher G, Boulanger P, Chapdelaine A (1990) Steroid metabolism and binding in relation to prostatic cell growth and differentiation in vitro. Ann NY Acad Sci 595:173–183
Geldof AA, Rao BR, de Voogt HJ (1986) Direct effects of chemotherapeutic agents on rat prostate tumor clonogenic cells. Anticancer Res 6:837–840
Geldof AA, de Voogt HJ, Rao BR (1987) Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H). Prostate 11:281–290
Geller J, Albert JD, Nachtsheim DA, Loza D (1984) Comparison of prostate cancer tissue, dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 132:693–696
Huggins C, Hodges CV (1941) Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injection on the normal and on the hyperplastic prostate glands of dogs. Cancer Res 1:293–297
Kadohama N, Karr JP, Murphy GP, Sandberg AA (1984) Selective inhibition of prostatic tumor 5α-reductase by a 4-methyl-4-azasteroid. Cancer Res 44:4947–4954
Kadohama N, Wakisaka M, Kim U, Karr JP, Murphy GP, Sandberg AA (1985) Retardation of prostate tumor progression in the Noble rat by 4-methyl-4-aza-steroidal inhibitors of 5α-reductase. J Natl Cancer Inst 74:475–486
Labrie F, Dupont A, Belanger A (1983) New approach in the treatment of prostate cancer: complete instead partial withdrawal of androgens. Prostate 4:579–583
Labrie C, Trudel C, Li S, Martel C, Couë J, Labrie F (1991) Combination of an antiandrogen and a 5α-reductase inhibitor: a further step towards total androgen blockade? Endocrinology 128:1673–1675
Liang T, Heiss CE (1981) Inhibition of 5α-receptor binding and nuclear uptake of androgens in the prostate by a 4-methyl-4-aza steroid. J Biol Chem 256:7998–8005
Liang T, Heiss CE, Ostrove S, Rasmusson GH, Cheung A (1983a) Binding of a 4-methyl-4aza-steroid to 5α-reductase of rat liver and prostate microsomes. Endocrinology 112:1460–1468
Liang T, Rasmusson GH, Brooks JR (1983b) Biochemical and biological studies with 4-methyl-4-aza-steroidal 5α-reductase inhibitors. J Steroid Biochem 19:385–390
Metcalf BW, Levy MA, Holt DA (1989) Inhibitors of steroid 5α-reductase in benign prostatic hyperplassia, male pattern baldness and acne. Trends Pharmacol Sci 10:491–495
Rao BR, Geldof AA, van der Wilt CL, de Voogt HJ (1988) Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer. Prostate 13:69–78
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Geldof, A.A., Meulenbroek, M.F.A., Dijkstra, I. et al. Consideration of the use of 17β-N,N-diethylcarbamoyl-4-methyl-4-aza-5-α-androstan-3-one (4MA), a 5α-reductase inhibitor, in prostate cancer therapy. J Cancer Res Clin Oncol 118, 50–55 (1992). https://doi.org/10.1007/BF01192311
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01192311